Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Stock Information for Tenax Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tenax Therapeutics Inc.

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.